Carcinoma, Adenosquamous

Phase 3 trials (3)

• figitumumab
• paclitaxel
• carboplatin

Phase 2 trials (8)

• F 18-fluoroazomycin arabinoside
• aldesleukin
• sitagliptin
• cyclophosphamide
• young tumor infiltrating lymphocytes
• fludarabine
• cisplatin
• esk981

Phase 1 trials (2)

• autologous tumor infiltrating lymphocytes
• nivolumab

Organization Involved with Phase 3 Indications (7)

• Pfizer
• National Cancer Institute (NCI)
• Canadian Cancer Trials Group
• Harvard University
• Eastern Cooperative Oncology Group
• Gynecologic Oncology Group
• NRG Oncology

Organization Involved with Phase 2 Indications (14)

• Celgene
• Advaxis, Inc.
• Eurofarma Laboratorios S.A.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• National Institutes of Health (NIH)
• AIDS Malignancy Consortium
• Cancer Treatment Centers of America
• Johns Hopkins University
• Parirenyatwa Hospital
• Radiation Therapy Oncology Group
• University of Toronto
• Fujian Medical University
• Southern Medical University
• Yeshiva University

Organization Involved with Phase 1 Indications (7)

• Bristol-Myers Squibb
• University of Pittsburgh
• University of South Florida
• Mayo Clinic
• Stand Up To Cancer
• Prometheus Inc.
• Iovance

Organization Involved with Other Experimental Indications (1)

• Southwest Oncology Group